A team of investigators from Notre Dame has developed a blood-based test that they say can diagnose glioblastoma in less than an hour. The new diagnostic uses an electrokinetic technology that is capable of detecting epidermal growth factor receptors (EGFRs), which are known to be overexpressed in glioblastoma and other…

In a significant advancement for glioblastoma treatment, researchers at The University of Texas MD Anderson Cancer Center have discovered that natural killer (NK) cells engineered to express interleukin-21 (IL-21) show powerful and sustained antitumor activity against glioblastoma stem cell-like cells (GSCs). Reporting in Cancer Cell, the scientists present the first…

Researchers in Germany report they have found islands of highly potent immune cells in the bone marrow of the skull neighboring glioblastoma, a surprising discovery that provides a prospective new avenue for the development of therapies to fight the most common form of brain cancer. Until now, the common notion…

Researchers at the University of Florida report they have developed an mRNA cancer vaccine that quickly reprograms the immune system to attack glioblastoma in a first-ever human clinical trial of four adult patients. Their results published in Cell mirror those from preclinical mouse studies, and from a newly reported trial…

Researchers at the University of California, San Francisco (UCSF) have begun enrollment for a clinical trial that uses a new, powerful version of CAR T as a potential therapy for glioblastoma, the most common and deadly adult brain cancer. The clinical trial is funded by an $11 million grant to…

Researchers at the Gladstone Institutes have developed a CRISPR-based “genome shredding” technique that shows promise in treating glioblastoma, an incurable brain cancer. Their research was published this week in the journal Cell Reports. Much of the work done to develop the technique was done in the lab of Jennifer Doudna,…

Mayo Clinic Comprehensive Cancer Center and Columbia University have been awarded a five-year, $10.6 million grant from the National Cancer Institute (NCI) to advance glioblastoma research. The grant will support a team of researchers to develop the Mathematical Oncology Systems Analysis Imaging Center (MOSAIC), which will combine biopsies collected at…

Cerebrospinal fluid (CSF), the clear colorless liquid that protects the brain, also may be a factor that makes brain cancers resistant to treatment, according to new work from researchers led by Cedric Bardy at the South Australia Health and Medical Research Institute (SAHMRI) and Flinders University. Their study appeared last…

Investigators at the University of Texas MD Anderson Cancer Center has developed a potentially groundbreaking method for enhancing immunotherapy responses in glioblastoma by using extracellular vesicles loaded with messenger RNA (mRNA). This new approach, detailed in Nature Communications, has solved some of the hurdles faced by mRNA-based therapy approaches for…

Early-stage research led by Brigham and Women’s Hospital shows that an engineered virus can significantly increase survival in patients with recurring glioblastoma brain tumors who have limited or no other treatment options. The engineered virus—CAN-3110—was created by U.S. biotech Candel Therapeutics, which has a focus on creating novel immunotherapies to…

A Phase II clinical trial being led by researchers at Dana-Farber Cancer Institute along with 10 brain tumor centers across the U.S. is taking an efficient and innovative method to find new potential treatments for glioblastoma. While the adaptive platform trial has not shown any of the three therapeutics tested…

Groundbreaking research from the University of Nottingham in the U.K. has shown how the self-destruction of glioblastoma cells can be triggered by harnessing the power of electromagnetic fields via miniature bio-nanoantennae. Although still in the early stages of development, the technology has the potential to make a huge impact on…

A team of researchers at the Hospital for Sick Children (SickKids) in Toronto, have demonstrated a designer peptide targeting a protein-protein interaction that could become a treatment for glioblastoma. The discovery of a previously unknown target, reported today in the journal Nature Cancer, could provide a new method to treat…

New evidence suggests lymph nodes play a key role in why tumors that have spread to the brain respond to immunotherapy, while glioblastoma, which originates in the brain, does not. “Typically, antigen presenting cells (e.g., conventional dendritic cells, cDCs) are recruited to the tumor, where they phagocytose dead or dying tumor…

Salk scientists have found the immunotherapy treatment anti-CTLA-4 leads to considerably greater survival of mice with mesenchymal glioblastoma. Furthermore, they discovered that this therapy relied on CD4+ T cells infiltrating the brain and triggering the tumor-destructive activities of immune cells called microglia, which permanently reside in the brain. Published in Immunity,…